Ascelia Pharma – Presentation of Half-Year Report 2023

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma – Wednesday 23 August at 10.00 CEST.

It’s been a busy first half-year for Ascelia Pharma and besides the financials CEO Magnus Corfitzen will run through the major highlights and what to expect in the second half of 2023.

Ascelia Pharma is a Swedish biotech company that focuses on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia Pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detection and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 11:00 – 04-07-2023.